News & Events

Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR’s Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma

KAHR, a clinical-stage biotech company developing a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and adaptive immunity to treat solid tumors and blood cancers, and the Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in KAHR to explore the potential of DSP107, KAHR’s lead immunotherapy drug candidate, for the treatment of multiple myeloma.


“We are thrilled to partner with KAHR to help advance DSP107 as a potential drug candidate for multiple myeloma,” said Peter Kosa, Ph.D., Managing Director of the Myeloma Investment Fund. “This investment reinforces our commitment to drive the development of the most innovative treatment approaches for myeloma patients.”


“We are excited to have the Myeloma Investment Fund join our syndicate of investors,” said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. “This vote of confidence helps us advance the clinical development of our lead product candidate, DSP107, which is being tested in multiple clinical studies for the benefit of patients who are non-responsive or refractory to existing therapies.”


Together with the current investment, KAHR has raised a total of $59 million since June 2021 in private placements supported by aMoon Fund, Flerie Invest AB, Peregrine Ventures, BVF Partners LP, DAFNA Capital Management LLC, Consensus Business Group, Hadasit Bio Holdings Ltd (HBL), Mirae Asset, Shavit Capital, Pavilion Capital, Cancer Focus Fund and Remedii.